Angelini Pharma and Quiver Bioscience Partner on AI-Powered Genetic Epilepsy Research

Angelini Pharma and Quiver Bioscience have entered a multi-year research and licensing agreement to develop novel therapeutics for genetic epilepsies, announced in a press release.

Under the agreement, Angelini Pharma secures exclusive global license rights to drug targets identified during the collaboration. Quiver will receive an undisclosed upfront payment, research funding, and potential milestone payments of up to $120 million, as well as royalties on future products.

The partnership combines Quiver’s AI-driven drug discovery platform, which integrates human neuronal models and single-cell data, with Angelini Pharma’s expertise in brain health and epilepsy drug development. The goal is to identify and advance new treatments for developmental and epileptic encephalopathies, a group of rare childhood disorders characterized by severe, treatment-resistant seizures.

Angelini Pharma will have exclusive access to collaboration-generated data during the research term. The companies aim to generate a comprehensive dataset to accelerate the discovery of precision therapies for multiple genetic epilepsy conditions.